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Abstract
The model of infrarenal aortocaval fistula (ACF) has recently gained new interest in its use to investigate cardiac
pathophysiology. Since in previous investigations the development of congestive heart failure (CHF) was inconsistent and
started to develop earliest 8–10 weeks after fistula induction using a 18G needle, this project aimed to induce a predictable
degree of CHF within a definite time period using a modified approach. An aortocaval fistula was induced in male Wistar
rats using a 16G needle as a modification of the former 18G needle-technique described by Garcia and Diebold. Results
revealed within 2862 days of ACF significantly increased heart and lung weight indices in the ACF group accompanied by
elevated filling pressure. All hemodynamic parameters derived from a pressure-volume conductance-catheter in vivo were
significantly altered in the ACF consistent with severe systolic and diastolic left ventricular dysfunction. This was
accompanied by systemic neurohumoral activation as demonstrated by elevated rBNP-45 plasma concentrations in every
rat of the ACF group. Furthermore, the restriction in overall cardiac function was associated with a b1- and b2-
adrenoreceptor mRNA downregulation in the left ventricle. In contrast, b3-adrenoreceptor mRNA was upregulated. Finally,
electron microscopy of the left ventricle of rats in the ACF group showed signs of progressive subcellular myocardial
fragmentation. In conclusion, the morphometric, hemodynamic and neurohumoral characterization of the modified
approach revealed predictable and consistent signs of congestive heart failure within 2862 days. Therefore, this modified
approach might facilitate the examination of various questions specific to CHF and allow for pharmacological interventions
to determine pathophysiological pathways.
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Introduction
Despite improvements in the treatment of congestive heart
failure (CHF), CHF is still associated with a high mortality. The
overall prevalence of CHF is still increasing because of the ageing
of the population and the success in prolonging survival in patients
suffering cardiac disease [1]. Therefore, the number of patients
with CHF scheduled for surgery with a consecutive increase in the
perioperative risk, especially in high-risk-procedures, e.g. vascular
and cardiothoracic surgery, is growing. However, knowledge
about the underlying pathophysiological mechanisms, which
promote heart failure in the perioperative course resulting in
biventricular volume overload remains scarce. Thus, it would be of
advantage to have a reproducible and predictable experimental
model of heart failure developing within a brief time period.
CHF is a multicausal state in which the heart is unable to deliver
an appropriate amount of substrates and oxygen to the tissues [2].
This has been reflected in several experimental animal models
with distinct pathophysiological causes: a) coronary ligation – loss
of cardiomyocytes, b) aortic banding – pressure overload, c) salt
sensitive hypertension – pressure overload, d) genetic models – loss
of cardiomyocytes or pressure/volume overload, e) toxic cardio-
myopathies – loss of cardiomyocytes [3] and finally f) infrarenal
aortocaval fistula (ACF) – volume overload [4].
The experimental model of volume overload induced by an
aortocaval fistula was first published by Holman in 1937 and has
been established with slight modifications by Garcia and Diebold
since 1990 [5]. However, in previous investigations of ACF
induced volume overload, heart failure was inconsistent and
started to develop earliest 8–10 weeks after fistula induction using
a 18G-needle [4,6]. In a study by Melenovsky et al. overt signs of
CHF became first obvious at approximately 20 weeks after ACF
placement in male Wistar rats [7] and were only present in 65% at
the 22th week [8].
Therefore, in this project we aimed to induce a predictable
degree of CHF in every animal within a definite time period using
a modified approach (16G needle) of the previously published 18G
needle-technique by Garcia and Diebold [5]. Such a model would
facilitate the examination of various questions specific to CHF and
would allow for precisely timed pharmacological interventions to
determine pathophysiological pathways. 2862 days after ACF
induction, the extent of heart failure was determined morpholog-
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ically, and hemodynamically by means of an intraventricular
pressure-volume conductance catheter. Specific adaptations in
BNP plasma concentrations and the expression of the b1-, b2- and
b3-adrenoreceptor mRNA expression were examined in this
modified ACF model. Finally, electron microscopy should reveal
subcellular changes according to CHF.
Materials and Methods
Animals
Male Wistar rats, 280–300 g (Harlan Winkelmann, Borchen,
Germany), were maintained on standard laboratory rat chow and
water ad libitum. The animals were kept on a 12-h light–dark
cycle. This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the local care authories (Landesamt für Gesund-
heit und Soziales, Berlin, Germany) (Permit Number: G 0119/08).
All surgery was performed under isoflurane (ACF induction) and
tiletamine/zolazepam (hemodynamic measurements) anesthesia,
and all efforts were made to minimize suffering. Post surgical
analgesia was provided by metamizole (40 mg/kg s.c.).
Experimental model
The needle-technique to induce an infrarenal aortocaval fistula
(ACF) has previously been described by Garcia and Diebold using
a 18G needle [5]. Here, we modified this technique using a 16G
needle. Briefly, a laparotomy was performed and the aorta was
punctured with a 16G disposable needle (Braun, Melsungen,
Germany) distal to the renal arteries. Then, the needle was
advanced through the aortic wall into the adjacent inferior vena
cava. After temporarily compressing the aorta and venous vessels
above and below the puncture site, the needle was carefully
withdrawn and the aortic puncture site was sealed with a drop of
cyanoacrylate glue. Patency of the fistula ACF was visualized by
the pulsatile flow of oxygenated blood into the vena cava inferior
from the infrarenal aorta [9]. Vessels of sham-operated control
animals were also temporarily compressed and glued together, but
without any puncture of the aorta.
Hemodynamic measurements
For hemodynamic measurements the ‘‘closed chest’’ method in
spontaneously breathing rats was used as described earlier [10]. All
measurements were performed under tiletamine/zolazepam an-
esthesia (ZoletilH, 10 mg/kg s.c. followed by 50 mg/kg i.m.) 2862
days after fistula induction [11]. The rats were placed on a heating
pad to maintain body temperature. After tracheotomy a PE-50
tubing catheter was inserted via the left jugular vein into the
superior vena cava for assessment of central venous pressure.
Arterial blood pressure was measured by cannulating the right
carotid artery with a micro-tip pressure-volume conductance
catheter (MillarH, SPR-838 NR). By further advancing the
catheter into the left ventricle intraventricular pressures and
volumes were registered. The position of the catheter was
optimized aiming for maximal stroke volume (SV). For measure-
ment of the parallel conductance volume 100 ml of 15% saline
were injected into the central venous line to determine the
correction factor for the blood-LV tissue interface, however,
inhomogeneity of the electric field was not corrected. Heart rate
was derived from the ECG signal. After completion of cannulation
there was a 10–15 minute equilibration period before starting the
measurements. All measurements were performed in spontane-
ously breathing rats without mechanical ventilation. All signals
were recorded and analyzed by the PowerLabH-system and
software (ADInstruments, Dunedin, New Zealand). After comple-
tion of the hemodynamic measurements animals were killed by
exsanguination and organs were eviscerated for further determi-
nations.
Determination of BNP plasma concentration
Blood samples for rat brain natriuretic peptide 45 (rBNP-45)
determinations were withdrawn from control (n = 6) and ACF
(n = 6) animals into EDTA-preloaded tubes after completion of
hemodynamic measurements. The blood was centrifuged at 4uC
at 1,000 g for 10 min immediately after withdrawal, and the
plasma was maintained at 280uC until extraction. Plasma rBNP-
45 concentrations were measured by using a sensitive enzyme-
linked immunosorbent assay (ELISA) kit (Abnova, Heidelberg,
Germany) [12].
b1-, b2- and b3-adrenoreceptor RT-PCR
Tissue of the left ventricle for determination of b1-, b2- and b3-
adrenoreceptor (AR) mRNA was obtained from sham-operated
control (n = 6) and ACF (n = 6) animals after completion of
hemodynamic measurements. Following mRNA extraction from
rat cardiac tissue reverse transcription-polymerase chain reaction
(RT-PCR) analysis was performed as described previously [13]. In
brief, total RNA was prepared with the commercially available kit
Qiazol Lysis Reagent, (Qiagen, Hilden, Germany) according to
the manufacturer’s protocol. Then, 1 mg RNA determined by
Nanodrop (Peqlab, Erlangen, Germany) were used for transcrip-
tion to cDNA by using the Omniscript RT Kit (Qiagen) as follows:
0.5 mM dNTP, 5 mM random primer, 10 U RNase Inhibitor, and
4 U Omniscript reverse Transcriptase. Samples were incubated at
42uC for 1 hour, and cDNA was stored at 220uC. The following
primers were used: 59-CTGCTACAACGACCCCAAGTG-39
(forward) and 59-AACACCCGGAGGTACACGAA-39 (reverse)
for b1-AR [14], 59-GAGCCACACGGGAATGACA-39 (forward)
and 59-CCAGGCGATAACCGACATGA-39 (reverse) for b2-AR
[14] and 59-GCCGAGACTACAGACCATAACCA-39 (forward)
and 59-CATTACGAGGAGTCCCACTACCA-39 (reverse) for
b3-AR [15]. Taqman qRT-PCR was performed with a SYBR
Green kit following the manufacturer’s instructions (Applied
Biosystems, Foster City, CA). Experiments were repeated three
Table 1. Morphometric data.
Control (n = 6) ACF (n = 6)
BW (g) 370616 (330–419) 36669 (345–395)
Heart (mg) 1410649 (1270–1570) 24306113 (2000–
2730)*
Heart/BW (mg/g BW) 3.960.1 (3.5–4.1) 6.660.2 (5.7–7.0)*
Lung (mg) 1370643 (1270–1490) 26756204 (1930–
3170)*
Lung/BW (mg/g BW) 3.860.2 (3.2–4.5) 7.360.6 (5.6–9.1)*
Kidney (mg) 1192660 (1050–1340) 1160662 (950–1330)
Kidney/BW (mg/g BW) 3.360.1 (3.1–3.5) 3.260.1 (2.8–3.4)
Liver (mg) 128246877 (10620–15070) 137076976 (10350–
16500)
Liver/BW (mg(g BW) 35.061.6 (30.5–40.3) 37.462.4 (30.0–45.8)
Values are means 6 SEM and range; n = 6 rats/group. BW, body weight.
*indicates a statistically significant difference betwenn groups (p,0.001).
doi:10.1371/journal.pone.0087531.t001
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times. b1-, b2- and b3-AR mRNA was quantified by using
triplicates of samples with the ABI Prism 7500 sequence detection
system (Applied Biosystems, System Software v 1.3.1.) and the
delta-delta CT method. The housekeeping gene 18S rRNA (59-
CGGCTACCACATCCAAGGAA-39 forward and 59-
GCTGGAATTACCGCGGCT-39 reverse) was used as an
internal reference gene.
Electron microscopy
Rats of each group were anesthetized with tiletamine/
zolazepam (ZoletilH) (see above) and transcardially perfused with
100 ml warm saline, followed by 300 ml 4% paraformaldehyde/
0.1% glutaraldehyde/0.2% picric acid solution (pH 7.4) in 0.16 M
phosphate buffer solution (pH 7.4). After perfusion the hearts were
removed and postfixed for 3 hours at 4uC in the fixative solution.
Tissue of the left ventricle was processed for electron microscopy
as described previously [16].
Statistical analysis
All tests were performed using SPSS 20.0 software program.
Normal distribution was analyzed with the Kolmogorov-Smirnov
test. Results are expressed as means 6 SEM or median and
interquartile distance. Statistical significance between the two
groups was analyzed by Student t-test or Mann-Whitney test as
appropriate. P,0.05 was considered statistically significant.
Results
Increased heart and lung weight indices in rats with
aortocaval fistula
Values for organ weight, body weight, and the organ weight/
body weight ratio (‘‘index’’) are given in Table 1. Body weights
were not significantly different between the control and the ACF
group 2862 days after fistula induction. However, heart and lung
weight indices were significantly increased (p,0.01) at 2862 days
Figure 1. Representative pressure-volume loops of a sham-operated control rat (top) and an ACF rat (bottom).
doi:10.1371/journal.pone.0087531.g001
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after induction of the aortocaval fistula. Considering technical
aspects of the here presented approach, the main complication was
uncontrollable bleeding at the puncture site at ACF induction.
However, after a learning phase (approximately 30 animals) which
resulted in proper needle handling, i.e a) careful puncture of the
anterior aortic wall not injuring the posterior wall, and b) very
gentle advancement of the needle into the vena cava inferior,
perioperative mortality was ,1%. During progression into heart
failure 2862 days mortality in a cohort of 23 animals was 17%
(n = 4). Out of the remaining 19 rats n = 6 sham rats and n = 6
ACF rats were used for the morphometric, hemodynamic,
neurohumoral, and beta-adrenergic mRNA measurements. In
addition, n = 2 sham rats and n = 5 ACF rats were used for
electron microscopy.
Systolic and Diastolic Dysfunction in ACF rats
Values for various hemodynamic parameters of the control and
ACF groups are shown in Table 2. Central venous (CVP) and left
end-diastolic pressure (LV-EDP) were significantly increased in
ACF rats (p,0.01). Systolic and diastolic arterial blood pressures
(SBP, DBP) were significantly reduced due to afterload reduction
in rats with an aortocaval fistula (p,0.01). Cardiac output was
nearly doubled in the ACF group. This was based on a nearly
doubled stroke volume (p,0.01) forming a characteristic pressure-
volume-loop in fistula-operated animals (Fig. 1 A and B). Left
ventricular end-diastolic and end-systolic volumes (LVEDV,
LVESV) were significantly higher than in the control group (p,
0.01). However, left ventricular ejection fraction (LVEF) (p,0.01)
and the maximum rate of pressure development (p,0.01) were
significantly reduced. There was no overlap in the data
distribution between a) ACF rats with increased heart and lung
weight indices and decreased LVEF and b) control rats.
Furthermore, a slowed cardiac relaxation became apparent as a
reduced maximum rate of pressure decay (p,0.01) and prolonged
time of Tau (p,0.01).
Increased rBNP-45 plasma concentration in rats with
heart failure
Values for the rBNP-45 plasma concentration from the control
and ACF groups are shown in Figure 2. rBNP-45 plasma
concentrations were significantly increased in the ACF group.
Table 2. Hemodynamic data.
Control (n = 6) ACF (n = 6)
HR (min21) 386613 (345–420) 345614 (301–373)
SBP (mmHg) 15567 (131–180) 12266 (106–148)*
DBP (mmHg) 11469 (72–134) 6962 (63–76)*
LVEDP (mmHg) 5.060.3 (3.9–6.3) 13.961.3 (9.9–16.7)*
CVP (mmHg) 0.260.1 (0.0–0.7) 6.460.8 (3.6–8.4)*
dP/dt max. (mmHg/s) 1587661128 (12143–18562) 902461207 (5616–13974)*
dP/dt min. (mmHg/s) 296756880 (213344–27715) 257916702 (28714–23614)*
Tau (ms) 8.060.4 (6.80–9.53) 13.461.1 (9.71–17.87)*
Elastance (mmHg/ml) 1.0160.11 (0.68–1.32) 0.3860.03 (0.31–0.48)*
LVEDV (ml) 18868 (166–220) 633651 (403–736)*
LVESV (ml) 4862 (41–56) 400638 (251–508)*
SV (ml) 14067 (125–170) 233624 (152–334)*
CO (ml/min) 5464 (46–71) 81610 (46–121)*
LVEF (%) 7461 (72–77) 3762 (30–45)*
Values are means 6 SEM and range; n = 6 rats/group. BW, body weight.
*indicates a statistically significant difference between groups (p,0.05).
HR = heart rate; SBP = systolic blood pressure; DBP = diastolic blood pressure; LVEDP = left ventricular enddiastolic pressure; CVP = central venous pressure; dP/dt
max. = maximum rate of pressure change of the left ventricle in systole; dP/dt min. = minimum rate of pressure change of the left ventricle in diastole; Tau = isovolumic
relaxation constant; LVEDV = left ventricular enddiastolic volume; LVESV = left ventricular endsystolic volume; SV = stroke volume; CO = cardiac output; LVEF = left
ventricular ejection fraction.
doi:10.1371/journal.pone.0087531.t002
Figure 2. Total rBNP-45 plasma concentrations of control and
ACF rats. There was no overlap in data distribution meaning ACF
animals could be clearly distinguished from healthy animals. * indicates
a statistically significant difference between both groups (p,0.01, n = 6
per group).
doi:10.1371/journal.pone.0087531.g002
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Again, there was no overlap in data distribution between control
rats and ACF rats.
b1- and b2-AR mRNA downregulation in the LV
Values for the b1-, b2- and b3-adrenoreceptor mRNA from the
control and fistula groups are shown in Figure 3. b1- and b2-
adrenoreceptor mRNA expression was significantly decreased in
the fistula group (p,0.01) (Fig. 3 A and B).
b3-AR upregulation 28 days after shunt induction
In contrast to the significant downregulation of b1- and b2-
adrenoreceptor mRNA in the left ventricle (LV) of rats 2862 days
after shunt induction, b3-adrenoreceptor mRNA of the LV was
significantly upregulated in rats with an aortocaval fistula (p,0.01)
(Fig. 3 C).
Signs of progressive subcellular fragmentation in the
myocardium of rats with an aortocaval fistula
A representative example of the changes of the subcellular
myocardial structure is given in Figure 4. The electron microscopy
image of the LV of rats in the ACF group showed: a) fragmented
nuclear chromatin, b) reduced size of myofibrils, c) swollen
mitochondria, d) vacuolization, e) dissolved cell-cell-contacts with
degenerative appearances, and f) immigration of phagocytic
leukocytes. This might suggest apoptotic changes in the left
ventricle myocardium during the progressive course of heart
failure.
Discussion
In previous publications heart failure was inconsistent and
started to develop earliest $8 weeks after fistula induction using a
18G-needle [4,6]. Therefore, our goal was to modify the needle-
technique to achieve a predictable CHF within a short time period
to facilitate interventional studies with an improved assay
Figure 3. Fold change in b1- (A), b2- (B) and b3- (C) AR mRNA expression in the left ventricle of control and ACF rats. * indicates a
statistically significant difference between both groups (p,0.01, n = 6 per group).
doi:10.1371/journal.pone.0087531.g003
Figure 4. Electron microscopy in rats 4 weeks after induction of an aortocaval shunt (right) showing a) fragmented nuclear
chromatin (#), b) reduced size of myofibrils ( ), c) swollen mitochrondria (r), d) vacuolization (R), e) dissolved cell-cell-contacts
with degenerative appearances (*) and f) immigration of phagocytic leukocytes (1). Magnification: 610.000.
doi:10.1371/journal.pone.0087531.g004
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sensitivity. In this context, we used a 16G instead of a 18G needle,
which theoretically resulted in 69% larger cross-sectional area of
the fistula inducing a more pronounced cardiac volume overload
to hasten the pathophysiological processes. In animals of the 16G
needle ACF group, our findings met criteria to characterize a
severe CHF already after 28 days: 1) LV end-diastolic volume .
550 ml [4], 2) lung mass .2500 mg [6,17], 3) significant increase
(.50%) in heart weight to body weight ratio compared with the
control group and/or a heart weight index $5,0 mg/g BW
[17,18], and 4) elevated central venous pressure $4 mmHg [18].
As a new finding and in contrast to the previous studies using
different fistula induction methods, e.g. microsurgery vs. different
sized needles [4,9,19–21], these end points were reached within 4
weeks in every single rat of the here presented ACF group.
In vivo hemodynamic assessment of rats by means of a pressure-
volume catheter has become the gold standard - besides
echocardiography - in experimental models investigating adaptive
changes due to myocardial infarction [22] or volume overload
[23]. In using this modified approach, a complete hemodynamic
characterization derived from a conductance catheter in vivo in this
modified approach is shown for the first time. Intraventricular
pressures and volumes in the control group were comparable to
values previously published for healthy rats [10,23,24]. A nearly
two-fold increase in the lung weight index accompanied by
elevated central venous and left end-diastolic pressures denotes
backward failure (‘‘pulmonary congestion’’). Finally, we demon-
strated a clear separation between an increased heart and lung
weight indices and a reduced LVEF in every ACF animal
compared to every animal in the control group. This clearly
depicts the transition from eccentric hypertrophy with preserved
cardiac function to severe biventricular dilatation with decom-
pensated heart failure due to pronounced volume overload in our
modified approach [4,7,25,26].
Today, progressive heart failure has been recognized to develop
from a combination of genetic, neurohumoral, inflammatory [27],
and biochemical factors. Therefore, biomarkers have become
important for clinical risk stratification. Beside Troponin in the
case of acute coronary syndrome [28], BNP is one of the most
interesting biomarkers to grade the extent of heart failure to
support medical decisions making and to monitor responses to
therapy [29,30]. An increase in BNP plasma concentration reliably
reflects the neurohumoral activation due to persistent hemody-
namic overload of the heart [31]. 2862 days after fistula induction
BNP plasma concentrations were significantly increased in our
modified experimental model. This is consistent with previous
results by Langenickel et al. demonstrating the superiority of
cardiac BNP mRNA expression as a marker of the transition from
compensated to overt heart failure in volume overloaded rats [17].
Also, subcellular fragmentation consistent with apoptotic
changes of the myocardium has been recognized as an important
pathophysiological mechanism promoting progression of heart
failure [32–34]. This holds true for several causes of heart failure,
including myocardial infarction [35], and pressure [36] and
volume overload [37]. As an additional new finding in our
modified experimental approach, we were able to demonstrate
sites of severe subcellular fragmentation in cardiomyocytes of the
left ventricle 2862 days after fistula induction. This is extending
previous findings which demonstrated a) increased apoptotic rate
of the myocardium only 16 weeks after ACF induction using a
18G needle [37], and b) mainly in non-cardiomyocytes [38].
However, further studies have to confirm these data.
Abnormalities in myocardial catecholamine release and in b-
adrenergic receptor (AR) density in patients with congestive heart
failure have long been recognized [39,40]. Adrenergic over-
activity is one of the hallmarks of the heart failure syndrome and is
associated with a poor prognosis [41–43]. As early as 1992,
Hammond et al. reported blunted heart rate responsiveness to b1-
AR stimulation in volume overloaded pigs due to b1-AR
downregulation 5 weeks after fistula induction [44]. In failing
human myocardium, b1-ARs are downregulated as studied with
quantitative polymerase chain reactions in dilated and ischemic
cardiomyopathy [45]. Also, Ihl-Vahl et al. were able to describe a
decrease in mRNA-levels of beta 2-adrenergic receptors in the
failing human heart [46]. In our results we demonstrate a b1- and
b2-adrenoreceptor mRNA downregulation in the LV in rats with
heart failure.
Almost two decades ago, the b3-adrenorecptor (b3-AR) has
been identified in myocardial tissue [47]. In healthy myocardial
tissue from rodents or humans, the mainly Gi-protein coupled b3-
AR is only scarcely expressed. However, according to current
knowledge [48–50], the b3-AR is upregulated in the failing heart
of the ACF group which is consistent with our data from the ACF
group.
In conclusion, our modified experimental model of heart failure
using a 16G needle to induce an infrarenal aortocaval fistula has
major advantages to investigate cardiac pathophysiology: conges-
tive heart failure can reproducibly be induced within a relatively
short and convenient time period. Combining morphometric,
hemodynamic and biochemical parameters, the extent of heart
failure can be well characterized. This modified model might
facilitate the examination of various questions concerning CHF
specifically by precisely timed interventions to determine patho-
physiological pathways.
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